PATENT CLAIM ANALYSIS

Application Number: 16030818
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["514", "265000"]

Abstract:
Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH 2 —, or K and L, considered in combination, are —CH 2 —. The R 1  moiety can be —NH 2 , C 1 -C 6  alkyl, C 1 -C 6  alkoxy, or C 1 -C 6  hydroxyalkyl. The R 2  and R 3  moieties are each independently C 1 -C 6  alkyl. The R 4  moiety is hydrogen or C 1 -C 6  alkyl. The R 5  and R 6  moieties are each independently C 6 -C 12  aryl, C 3 -C 8  cycloalkyl, or C 3 -C 8  heteroaryl, that is optionally further substituted.

Claim (Index 5):
The adenosine kinase inhibitor of  claim 1 , wherein where R 5  or R 6  is an aryl substituent, the aryl substituent is optionally and independently further substituted one or more times by halogen, C 1 -C 6  haloalkyl, C 1 -C 6  hydroxyalkyl, C 1 -C 6  alkoxy, sulfonyloxy, carboxyalkyl, nitro, C 1 -C 6  sulfonyloxyalkyl, or arylcarbonyl.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 95.0
- Lexical Diversity: 2.38462
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15607379', '15039778', '13902076', '14662397', '15194911']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7097442001679618
- 35 USC 102 Novelty (BERT): 0.674548911958082
- Combined Prediction Score: 0.7062246713469738
- Mean Citation Score: 329.67946200000006
- Max Citation Score: 647.2978
- Similarity Product: 644.1911423665883

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test